RGIN (Regenicin) FCF Margin %: 0.00% (As of Mar. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Regenicin FCF Margin %?

Regenicin RGIN -99.00% FCF Margin % is 0.00% as of Mar. 2023.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Regenicin's Free Cash Flow for the three months ended in Mar. 2023 was $-0.33 Mil. Regenicin's Revenue for the three months ended in Mar. 2023 was $0.00 Mil. Therefore, Regenicin's FCF Margin % for the quarter that ended in Mar. 2023 was 0.00%.

As of today, Regenicin's current FCF Yield % is 0.00%.

The historical rank and industry rank for Regenicin's FCF Margin % or its related term are showing as below:


RGIN's FCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -81.28
* Ranked among companies with meaningful FCF Margin % only.

Regenicin FCF Margin % Related Terms

Regenicin FCF Margin % Historical Data

* Premium members only.

The historical data trend for Regenicin's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Regenicin FCF Margin % Chart

Regenicin Annual Data
Trend Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Regenicin Quarterly Data
Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

RGIN vs NOVNQ, TMBRQ, RGRX: FCF Margin % Comparison

For the Biotechnology subindustry, Regenicin's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenicin FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenicin's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Regenicin's FCF Margin % falls into.


Regenicin FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Regenicin's FCF Margin for the fiscal year that ended in Sep. 2022 is calculated as

FCF Margin=Free Cash Flow (A: Sep. 2022 )/Revenue (A: Sep. 2022 )
=-0.027/0
= %

Regenicin's FCF Margin for the quarter that ended in Mar. 2023 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2023 )/Revenue (Q: Mar. 2023 )
=-0.328/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Regenicin (RGIN) has a FCF Margin % of 0.00% as of Mar. 2023. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Regenicin and its competitors.
Is Regenicin's FCF Margin % too high?
Regenicin's current FCF Margin % is 0.00%.
How does Regenicin's FCF Margin % compare to NOVNQ and TMBRQ?
Regenicin's FCF Margin % of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Regenicin and its competitors. Regenicin's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Regenicin stock overvalued right now?
Regenicin (RGIN) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Regenicin (RGIN), the current FCF Margin % is 0.00% as of Mar. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Regenicin Business Description

Address 10530 Discovery Drive, Las Vegas, NV, USA, 89135
Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.